Aristea Completes $63 Million Series B Financing to Accelerate Clinical Development of Novel Immunotherapy Drugs for the Treatment of Orphan Diseases

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3zJlVRu
via IFTTT